

From: [Josephson, Scott Andy](#)
To: [Michael Carome](#)
Cc: [Annette Flanagan](#)
Subject: JAMA Neurology
Date: Monday, March 1, 2021 2:13:17 PM

Dr. Carome:

Thank you for your recent letter. In response, we have corrected the conflict of interest disclosure for Dr. Musiek as below to reflect for our readers the relationship between Eisai and Biogen regarding aducanamab. Dr. Musiek's relationship with Eisai has not involved aducanamab.

Sincerely,

Andy Josephson
Editor, JAMA Neurology

The correction has been published and the disclosure statement now reads:

“Conflict of Interest Disclosures: Dr Musiek reports grants from Eisai Pharmaceuticals, the National Institutes of Health, and Cure Alzheimer’s Fund outside of this work and consulting for Eisai Pharmaceuticals, which (along with Biogen) is involved in developing and commercializing aducanumab for treatment of Alzheimer disease.”

<https://jamanetwork.com/journals/jamaneurology/fullarticle/2773648>

S. Andrew Josephson MD
Chair, Department of Neurology
Carmen Castro Franceschi and Gladys K. Mitchell
Neurohospitalist Distinguished Professor
Weill Institute for Neurosciences
University of California, San Francisco
505 Parnassus Ave, Box 0114
San Francisco, CA 94143
For patient care matters: (415) 353-8897
For all other contacts including scheduling: (415) 476-1488
Andrew.Josephson@ucsf.edu